Table 3 Plasma levels of B-type natriuretic peptide (BNP), ELABELA, Apelin, and left ventricular ejection fraction (LVEF) in patients with HFpEF, HFmrEF, and HFrEF.

From: Decreased plasma ELABELA level as a novel screening indicator for heart failure: a cohort and observational study

Parameters

Non-HF (n = 119)

HF (n = 216)

HF (n = 216)

HFpEF (n = 191)

HFmrEF (n = 15)

HFrEF (n = 10)

Plasma BNP, pg/ml

55.1 ± 19.2

1788.2 ± 904.3***

1523.9 ± 218.9***

3795.5 ± 699.9***##

3826.0 ± 792.4***##

Plasma ELABELA, ng/ml

13.7 ± 3.0

8.4 ± 4.5***

8.8 ± 4.5***

6.3 ± 4.7***#

4.6 ± 3.0***##$

Plasma Apelin, pg/ml

51.9 ± 19.6

152.2 ± 68.9***

148.2 ± 25.6***

190.0 ± 27.7***

166.8 ± 11.0***

LVEF, %

64.3 ± 4.3

60.5 ± 8.7

63.1 ± 4.8

44.9 ± 2.6***###

35.1 ± 3.4***###$$$

  1. HEpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, Heart failure with reduced ejection fraction. ***P < 0.001 vs. Non-HF; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. HEpEF; $P < 0.05 and $$$P < 0.001 vs. HFmrEF.
Back to article page